Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 3.654
Filtrar
1.
J Wound Care ; 33(8): 570-576, 2024 Aug 02.
Artigo em Inglês | MEDLINE | ID: mdl-39137253

RESUMO

OBJECTIVE: Acute laceration wound (ALW) is one of the most common injuries in Indonesia with potential significant morbidities. In rural areas, povidone-iodine and honey are commonly used as wound dressings. This study aimed to identify the effectiveness of honey compared to paraffin gauze and the commonly used povidone-iodine in improving ALW healing time. METHOD: This study was a single-blind, pilot randomised controlled trial (RCT) with three intervention groups (honey, povidone-iodine, and paraffin). The outcomes were wound healing time, slow healing, secondary healing, signs of infection, wound dehiscence, oedema, maceration, necrosis, exudate and cost. RESULTS: A total of 35 patients (male to female ratio: 4:1), with a mean age of 22.5 (range: 6-47) years, were included and randomised to treatment groups using predetermined randomisation according to wound location and wound dressing selection: honey group, n=12; povidone-iodine group, n=11; paraffin group, n=12 with one patient lost to follow-up. All groups achieved timely healing, with a mean healing time of 9.45±5.31 days and 11.09±5.14 days for the povidone-iodine and paraffin groups, respectively, and a median healing time of 10 (3-19) days for the honey group (p>0.05). More wounds in the honey group achieved healing in ≤10 days compared with the other groups. Both povidone-iodine and honey groups had fewer adverse events, with the latter having the lowest cost. CONCLUSION: In this study, honey was clinically effective in accelerating healing time with a lower cost compared to paraffin, and was comparable to povidone-iodine. Future RCTs with a larger sample size should be pursued to determine honey's role in ALW treatment.


Assuntos
Anti-Infecciosos Locais , Mel , Lacerações , Povidona-Iodo , Cicatrização , Humanos , Povidona-Iodo/uso terapêutico , Cicatrização/efeitos dos fármacos , Masculino , Feminino , Adulto , Projetos Piloto , Pessoa de Meia-Idade , Adolescente , Método Simples-Cego , Anti-Infecciosos Locais/uso terapêutico , Lacerações/terapia , Adulto Jovem , Criança , Indonésia , Bandagens , Parafina/uso terapêutico , Resultado do Tratamento
2.
J Craniofac Surg ; 35(5): 1507-1508, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39042072

RESUMO

Cerebrospinal fluid (CSF) rhinorrhea is one of the most common complications after trans-sphenoidal surgery. At present, transcranial or endoscopic surgery for CSF leakage requires general anesthesia to remove autologous fat or fascia to repair the leak, which is traumatic and costly. The authors present a case of a 25-year-old male patient with pituitary adenoma who experienced CSF rhinorrhea 10 days after undergoing endoscopic resection of the tumor. The authors innovatively sequential filled the leak with a gelatin sponge soaked in povidone-iodine solution and iodinated gauze under outpatient nasal endoscopy. The follow-up of 6 months showed no recurrence of CSF leakage. CSF leakage is the most common complication of trans-sphenoidal surgery. The authors suggest that for small cerebrospinal fluid leaks in the early stage after trans-sphenoidal surgery, the leakage should be first filled with gelatin sponge and iodoform gauze sequentially under outpatient nasal endoscopy, which may achieve a complete cure.


Assuntos
Rinorreia de Líquido Cefalorraquidiano , Endoscopia , Neoplasias Hipofisárias , Humanos , Masculino , Rinorreia de Líquido Cefalorraquidiano/cirurgia , Adulto , Neoplasias Hipofisárias/cirurgia , Endoscopia/métodos , Adenoma/cirurgia , Povidona-Iodo/uso terapêutico , Complicações Pós-Operatórias , Esponja de Gelatina Absorvível/uso terapêutico
3.
Epidemiol Mikrobiol Imunol ; 73(2): 98-105, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39060100

RESUMO

The novel personal protection equipment based on a face mask equipped with a nanofiber filter functionalized with povidone iodine has been developed and tested in a clinical trial. This nanofiber filter was characterized with a low flow resistance and, thus, allowed comfortable breathing. The performed study proved that the novel nanofiber filter with incorporated povidone-iodine was characterized with a slow release of iodine which minimized side effects but kept disinfection efficiency. Our clinical study performed on 207 positively tested SARS-CoV-2 patients wearing the PPE for 4-8 hours daily for 1 to 4 days has shown that even the iodine amount as low as 0.00028 ppm was sufficient to significantly decrease the reproduction number and, very importantly, to protect against severe course of disease.


Assuntos
COVID-19 , Nanofibras , Povidona-Iodo , SARS-CoV-2 , Povidona-Iodo/uso terapêutico , Povidona-Iodo/administração & dosagem , COVID-19/prevenção & controle , Humanos , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , Infecções por Coronavirus/prevenção & controle , Betacoronavirus , Anti-Infecciosos Locais/administração & dosagem , Masculino , Feminino , Adulto , Máscaras , Equipamento de Proteção Individual , Pessoa de Meia-Idade
4.
ACS Macro Lett ; 13(8): 1056-1064, 2024 Aug 20.
Artigo em Inglês | MEDLINE | ID: mdl-39083757

RESUMO

Biomaterial-associated infections caused by bacteria pose a great threat to human health, and therefore, various antibacterial coatings have been developed to control bacterial infections. Povidone iodine (PVP-I) is a broad-spectrum antimicrobial agent without drug resistance to most pathogenic microorganisms and has been widely used in the clinic. However, its applications in the field of coatings are limited due to its strong water solubility. Here, we used initiated Chemical Vapor Deposition (iCVD) technique to synthesize cross-linked poly(N-vinylpyrrolidone-co-ethylene glycol dimethacrylate) (PVE) coatings to firmly immobilize poly(N-vinylpyrrolidone) (PVP) on surfaces. After complexation with iodine, PVE-I coatings exhibited potent bacteria-killing and antifouling activities against Gram-negative Escherichia coli and Gram-positive Staphylococcus aureus in vitro owing to the antibacterial effect of iodine and the hydrophilicity of VP, respectively. The killing and antifouling effects were positively correlated with the VP content. The PVE-I-2 coating displayed excellent anti-infection performance in a rat subcutaneous implantation model in vivo. This study provided a simple method for preparing stable povidone iodine coatings on surfaces via solvent-free iCVD, and combined bacteria-killing and antifouling strategies to fabricate multifunctional antibacterial coatings against bacterial infections on biomaterial surfaces.


Assuntos
Antibacterianos , Escherichia coli , Staphylococcus aureus , Antibacterianos/farmacologia , Antibacterianos/química , Antibacterianos/síntese química , Escherichia coli/efeitos dos fármacos , Staphylococcus aureus/efeitos dos fármacos , Animais , Ratos , Iodo/química , Iodo/farmacologia , Povidona-Iodo/farmacologia , Povidona-Iodo/química , Materiais Revestidos Biocompatíveis/farmacologia , Materiais Revestidos Biocompatíveis/química , Povidona/química , Testes de Sensibilidade Microbiana , Propriedades de Superfície
5.
Int J Biol Macromol ; 277(Pt 2): 134166, 2024 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-39084444

RESUMO

Superficial skin injuries especially burn injuries and unhealed diabetic foot open wounds remain troubling for public health. The healing process is often interrupted by the invasion of resistant pathogens that results in the failure of conventional procedures outside the clinical settings. Herein, we designed nanofibers dressing with intrinsic antibacterial potential of poly(vinyl-pyrrolidone)-iodine/ poly (vinyl)-alcohol by electrospinning with chitosan encapsulating ceftriaxone (CPC/NFs). The optimized electrospun CPC/NFs exhibited smooth surface morphology with average diameter of 165 ± 7.1 nm, drug entrapment and loading efficiencies of 76.97 ± 4.7 % and 8.32 ± 1.73 %, respectively. The results displayed smooth and uniformed fibers with adequate thermal stability and ensured chemical doping. The enhanced in vitro antibacterial efficacy of CPC/NFs against resistant E. coli isolates and biosafety studies encourage the use of designed nanofibers dressing for burn injuries and diabetic foot injuries. In vivo studies proved the healing power of dressing for burn wounds model and diabetic infected wounds model. Immunofluorescence investigation of the wound tissue also suggested promising healing ability of CPC/NFs. The designed approach would be helpful to treat these infected skin open wounds in the hospitals and outside the clinical settings.


Assuntos
Antibacterianos , Queimaduras , Ceftriaxona , Quitosana , Pé Diabético , Nanofibras , Cicatrização , Nanofibras/química , Pé Diabético/tratamento farmacológico , Pé Diabético/microbiologia , Quitosana/química , Quitosana/farmacologia , Queimaduras/tratamento farmacológico , Animais , Antibacterianos/farmacologia , Antibacterianos/química , Cicatrização/efeitos dos fármacos , Ceftriaxona/farmacologia , Ceftriaxona/química , Povidona-Iodo/farmacologia , Povidona-Iodo/química , Povidona-Iodo/administração & dosagem , Escherichia coli/efeitos dos fármacos , Masculino , Bandagens , Camundongos , Sistemas de Liberação de Medicamentos
6.
Viruses ; 16(7)2024 Jun 30.
Artigo em Inglês | MEDLINE | ID: mdl-39066225

RESUMO

Infectious diseases are a leading cause of losses in the aquaculture industry and conservation programs globally. Simultaneously, infectious diseases pose a substantial risk to fish being hatchery-reared and released into natural habitats for conservation purposes, including the Great Lakes lake sturgeon (Acipenser fulvescens, i.e., GL-LST). Recently, an alloherpesvirus (lake sturgeon herpesvirus 2, i.e., LSHV-2) capable of inducing disease and/or mortality in adult and juvenile GL-LSTs was detected in two adult GL-LST populations. To begin developing disease prevention and/or control methods, in vitro experiments were designed to determine the susceptibility of LSHV-2 to disinfectants commonly used in hatchery and aquaculture facilities (Virkon®-Aquatic: potassium peroxymonosulfate; Ovadine®: polyvinylpyrrolidone iodine complex; and Perox-Aid®: hydrogen peroxide). Cultured LSHV-2 was exposed to each disinfectant at two concentrations (Virkon®-Aquatic: 0.5% and 1%; Ovadine®: 50 and 100 ppm; and Perox-Aid®: 500 and 1000 ppm) in duplicate for durations of 1, 10, and 30 min. Following exposure, the disinfectant was neutralized, and after a 14-day incubation period on a white sturgeon × lake sturgeon hybrid cell line (WSxLS), percent reduction was calculated by comparing the 50% tissue culture infectious doses (TCID50/mL) of the virus with and without disinfectant exposure. When exposed to Perox-Aid®, LSHV-2 percent reduction ranged from 58.7% to 99.5%. When exposed to Ovadine®, the percent reduction ranged from 99.4% to 100%. Lastly, the percent reduction when exposed to Virkon®-Aquatic was 100% for both concentrations and all timepoints. The results herein provide evidence that both Virkon®-Aquatic and Ovadine® are virucidal to LSHV-2 and may represent a means to reduce virus transmission risk under field settings.


Assuntos
Desinfetantes , Doenças dos Peixes , Peixes , Herpesviridae , Animais , Desinfetantes/farmacologia , Peixes/virologia , Doenças dos Peixes/virologia , Doenças dos Peixes/prevenção & controle , Herpesviridae/efeitos dos fármacos , Aquicultura , Inativação de Vírus/efeitos dos fármacos , Lagos/virologia , Infecções por Herpesviridae/veterinária , Infecções por Herpesviridae/virologia , Infecções por Herpesviridae/prevenção & controle , Infecções por Herpesviridae/transmissão , Povidona-Iodo/farmacologia , Peróxido de Hidrogênio/farmacologia , Linhagem Celular , Peróxidos , Ácidos Sulfúricos
7.
Trials ; 25(1): 468, 2024 Jul 10.
Artigo em Inglês | MEDLINE | ID: mdl-38987786

RESUMO

BACKGROUND: With the increasing number of joint replacement surgeries, periprosthetic joint infection (PJI) has become a significant concern in orthopedic practice, making research on PJI prevention paramount. Therefore, the study will aim to compare the effect of combined usage of povidone-iodine and topical vancomycin powder to the use of povidone-iodine alone on the PJI incidence rate in patients undergoing primary total hip (THA) and total knee arthroplasty (TKA). METHODS: The prospective randomized clinical trial will be conducted in two independent voivodeship hospitals with extensive experience in lower limb arthroplasties. The studied material will comprise 840 patients referred to hospitals for primary THA or TKA. The patients will be randomly allocated to two equal groups, receiving two different interventions during joint replacement. In group I, povidone-iodine irrigation and consecutively topical vancomycin powder will be used before wound closure. In group II, only povidone-iodine lavage irrigation will be used before wound closure. The primary outcome will be the incidence rate of PJI based on the number of patients with PJI occurrence within 90 days after arthroplasty. The occurrence will be determined using a combined approach, including reviewing hospital records for readmissions and follow-up phone interviews with patients. The infection will be diagnosed based on Musculoskeletal Infection Society criteria. The chi-square test will be used to compare the infection rates between the two studied groups. Risk and odds ratios for the between-groups comparison purposes will also be estimated. Medical cost analysis will also be performed. DISCUSSION: A randomized clinical trial comparing the effect of combined usage of povidone-iodine irrigation and vancomycin powder to the use of povidone-iodine irrigation alone in preventing PJIs after primary arthroplasty is crucial to advancing knowledge in orthopedic surgery, improving patient outcomes, and guiding evidence-based clinical practices. TRIAL REGISTRATION: ClinicalTrials.gov NCT05972603 . Registered on 2 August 2023.


Assuntos
Administração Tópica , Antibacterianos , Anti-Infecciosos Locais , Artroplastia de Quadril , Artroplastia do Joelho , Povidona-Iodo , Infecções Relacionadas à Prótese , Ensaios Clínicos Controlados Aleatórios como Assunto , Irrigação Terapêutica , Vancomicina , Humanos , Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Anti-Infecciosos Locais/administração & dosagem , Artroplastia de Quadril/efeitos adversos , Artroplastia do Joelho/efeitos adversos , Incidência , Estudos Multicêntricos como Assunto , Povidona-Iodo/administração & dosagem , Pós , Estudos Prospectivos , Infecções Relacionadas à Prótese/prevenção & controle , Infecções Relacionadas à Prótese/epidemiologia , Irrigação Terapêutica/métodos , Resultado do Tratamento , Vancomicina/administração & dosagem
8.
J Hosp Infect ; 151: 99-108, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38992843

RESUMO

BACKGROUND: Chlorhexidine gluconate (CHG) and povidone-iodine (PI) are commonly used to prevent prosthetic joint infection (PJI) during total joint replacement; however, their effective concentrations and impact on biofilms are not well defined. AIM: To determine: (1) the in-vitro minimum inhibitory concentration of CHG and PI against model PJI-causing organisms and clinical isolates; (2) their impact on biofilm formation; (3) whether there is a synergistic benefit to combining the two solutions; and (4) whether adding the antibiotic vancomycin impacts antiseptic activity. METHODS: We measured in-vitro growth and biofilm formation of Staphylococcus epidermidis, meticillin-sensitive and meticillin-resistant Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Candida albicans, as well as recent clinical isolates, in the presence of increasing concentrations of CHG and/or PI. Checkerboard assays were used to measure potential synergy of the solutions together and with vancomycin. FINDINGS: CHG and PI inhibited growth and biofilm formation of all model organisms tested at concentrations of 0.0004% and 0.33% or lower, respectively; highly dilute concentrations paradoxically increased biofilm formation. The solutions did not synergize with one another and acted independently of vancomycin. CONCLUSION: CHG and PI are effective at lower concentrations than typically used, establishing baselines to support further clinical trials aimed at optimizing wound disinfection. There is no synergistic advantage to using both in combination. Vancomycin is effective at inhibiting the growth of S. epidermidis and S. aureus; however, it stimulates P. aeruginosa biofilm production, suggesting in the rare case of P. aeruginosa PJI, it could exacerbate infection.


Assuntos
Biofilmes , Clorexidina , Testes de Sensibilidade Microbiana , Povidona-Iodo , Infecções Relacionadas à Prótese , Vancomicina , Biofilmes/efeitos dos fármacos , Biofilmes/crescimento & desenvolvimento , Clorexidina/farmacologia , Clorexidina/análogos & derivados , Povidona-Iodo/farmacologia , Vancomicina/farmacologia , Infecções Relacionadas à Prótese/microbiologia , Infecções Relacionadas à Prótese/prevenção & controle , Humanos , Sinergismo Farmacológico , Anti-Infecciosos Locais/farmacologia , Antibacterianos/farmacologia , Candida albicans/efeitos dos fármacos , Bactérias/efeitos dos fármacos
10.
Sci Rep ; 14(1): 16739, 2024 07 20.
Artigo em Inglês | MEDLINE | ID: mdl-39033201

RESUMO

The aim of this study was to assess the profile of nasal microbiome and evaluate the effect of a specific nasal decolonization solution on the microbiome. We conducted a randomized, placebo-controlled, and parallel-group clinical study of 50 volunteers aged 18 years and older. The subjects were randomly assigned to receive a nasal antiseptic solution, containing povidone-iodine as the main ingredient, (n = 25) or a control solution (n = 25). Nasal swabs were obtained before application (baseline) and at 3 timepoints after application (5 min, 2 h, 24 h). Nasal swabs were subjected to next generation sequencing analysis and cultured in agar plates. At baseline, there were substantial associations between anaerobic species, Corynebacterium spp., Staphylococcus spp., and Dolosigranulum spp. Then, a high bioburden reduction was observed after the application of povidone-iodine (log10 3.68 ± 0.69 at 5 min; log10 3.57 ± 0.94 at 2 h; log10 1.17 ± 1.40 at 24 h), compared to the control. The top species affected by the treatment were Cutibacterium acnes, Staphylococcus, and Corynebacterium species. None of the subjects experienced any adverse effects, nor increases in mucociliary clearance time. Antiseptic solutions applied to the anterior nares can transiently and markedly reduce the bioburden of the nose. The registration number for this clinical trial is NCT05617729.


Assuntos
Anti-Infecciosos Locais , Microbiota , Povidona-Iodo , Humanos , Povidona-Iodo/farmacologia , Povidona-Iodo/administração & dosagem , Anti-Infecciosos Locais/farmacologia , Anti-Infecciosos Locais/administração & dosagem , Microbiota/efeitos dos fármacos , Masculino , Feminino , Adulto , Estudos Prospectivos , Pessoa de Meia-Idade , Nariz/microbiologia , Adulto Jovem , Bactérias/efeitos dos fármacos , Bactérias/classificação , Bactérias/genética , Administração Intranasal , Corynebacterium/efeitos dos fármacos
11.
Carbohydr Polym ; 340: 122217, 2024 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-38857997

RESUMO

Iodine (I2) as a broad-spectrum antiseptic has been widely used for treating bacterial infections. However, I2 has low water-solubility and sublimes under ambient conditions, which limits its practical antibacterial applications. The highly specific and sensitive reaction between I2 and starch discovered 200 years ago has been extensively applied in analytical chemistry, but the antibacterial activity of the I2-starch complex is rarely investigated. Herein, we develop a novel type of iodine-based antiseptics, iodine-soluble starch (I2-SS) cryogel, which can dissolve in water instantly and almost completely kill bacteria in 10 min at 2 µg/mL of I2. Although KI3 and the commercially available povidone­iodine (I2-PVP) solutions show similar antibacterial efficacy, the high affinity of I2 to SS largely enhances the shelf stability of the I2-SS solution with ∼73 % I2 left after one-week storage at room temperature. In sharp contrast, ∼8.5 % and âˆ¼2.5 % I2 are detected in KI3 and I2-PVP solutions, respectively. Mechanistic study reveals that the potent antibacterial effect of I2-SS originates from its attack on multiple bacterial targets. The outstanding antibacterial activity, capability of accelerating wound healing, and good biocompatibility of I2-SS are verified through further in vivo experiments. This work may promote the development of next-generation iodine-based antiseptics for clinical use.


Assuntos
Antibacterianos , Anti-Infecciosos Locais , Criogéis , Iodo , Solubilidade , Amido , Água , Iodo/química , Iodo/farmacologia , Amido/química , Amido/farmacologia , Antibacterianos/farmacologia , Antibacterianos/química , Anti-Infecciosos Locais/farmacologia , Anti-Infecciosos Locais/química , Água/química , Criogéis/química , Animais , Staphylococcus aureus/efeitos dos fármacos , Camundongos , Testes de Sensibilidade Microbiana , Povidona-Iodo/química , Povidona-Iodo/farmacologia , Escherichia coli/efeitos dos fármacos , Cicatrização/efeitos dos fármacos
12.
Antimicrob Resist Infect Control ; 13(1): 57, 2024 Jun 05.
Artigo em Inglês | MEDLINE | ID: mdl-38840171

RESUMO

AIM: Although uncommon, infections associated with peripheral intravenous catheters (PIVCs) may be responsible for severe life-threatening complications and increase healthcare costs. Few data are available on the relationship between PIVC insertion site and risk of infectious complications. METHODS: We performed a post hoc analysis of the CLEAN 3 database, a randomized 2 × 2 factorial study comparing two skin disinfection procedures (2% chlorhexidine-alcohol or 5% povidone iodine-alcohol) and two types of medical devices (innovative or standard) in 989 adults patients requiring PIVC insertion before admission to a medical ward. Insertion sites were grouped into five areas: hand, wrist, forearm, cubital fossa and upper arm. We evaluated the risk of risk of PIVC colonization (i.e., tip culture eluate in broth showing at least one microorganism in a concentration of at least 1000 Colony Forming Units per mL) and/or local infection (i.e., organisms growing from purulent discharge at PIVC insertion site with no evidence of associated bloodstream infection), and the risk of positive PIVC tip culture (i.e., PIVC-tip culture eluate in broth showing at least one microorganism regardless of its amount) using multivariate Cox models. RESULTS: Eight hundred twenty three PIVCs with known insertion site and sent to the laboratory for quantitative culture were included. After adjustment for confounding factors, PIVC insertion at the cubital fossa or wrist was associated with increased risk of PIVC colonization and/or local infection (HR [95% CI], 1.64 [0.92-2.93] and 2.11 [1.08-4.13]) and of positive PIVC tip culture (HR [95% CI], 1.49 [1.02-2.18] and 1.59 [0.98-2.59]). CONCLUSION: PIVC insertion at the wrist or cubital fossa should be avoided whenever possible to reduce the risk of catheter colonization and/or local infection and of positive PIVC tip culture.


Assuntos
Infecções Relacionadas a Cateter , Cateterismo Periférico , Humanos , Feminino , Masculino , Cateterismo Periférico/efeitos adversos , Infecções Relacionadas a Cateter/prevenção & controle , Infecções Relacionadas a Cateter/microbiologia , Pessoa de Meia-Idade , Idoso , Clorexidina , Adulto , Desinfecção/métodos , Povidona-Iodo , Fatores de Risco , Anti-Infecciosos Locais , Contaminação de Equipamentos , Punho/microbiologia
14.
J Orthop Surg Res ; 19(1): 360, 2024 Jun 18.
Artigo em Inglês | MEDLINE | ID: mdl-38890743

RESUMO

BACKGROUND: Periprosthetic joint infection after total joint arthroplasty has a large incidence, and it may often require two or more stages of revision, placing an additional burden on clinicians and patients. The purpose of this network meta-analysis is to evaluate the effect of four different preventive strategies during total joint arthroplasty on the prevention of periprosthetic joint infection. METHODS: The study protocol was registered at PROSPERO (CRD: 42,023,448,868), and the literature search databases included Web of Science, PubMed, OVID Cochrane Central Register of Controlled Trials, OVID EMBASE, and OVID MEDLINE (R) ALL that met the requirements. The network meta-analysis included randomized controlled trials, retrospective cohort studies and prospective cohort studies with the outcome of periprosthetic joint infection. The gemtc R package was applied to perform the network meta-analysis to evaluate the relative results of different preventive strategies. RESULTS: This network meta-analysis study included a total of 38 articles with 4 preventive strategies and negative controls. No improvement was observed in antibiotic-loaded bone cement compared with negative controls. Chlorhexidine showed the highest probability of delivering the best preventive effect, and povidone iodine had the second highest probability. Although vancomycin ranked after chlorhexidine and povidone iodine, it still showed a significant difference compared with negative controls. In addition, the incidence after applying chlorhexidine was significantly lower than that after applying negative controls and vancomycin. In the heterogeneity test between direct and indirect evidence, there was no apparent heterogeneity between them. CONCLUSION: The study indicated that chlorhexidine, povidone iodine and vancomycin showed significant efficacy in preventing periprosthetic joint infection after total joint arthroplasty, while antibiotic-loaded bone cement did not. Therefore, more high-quality randomized controlled trials are needed to verify the results above.


Assuntos
Metanálise em Rede , Infecções Relacionadas à Prótese , Humanos , Infecções Relacionadas à Prótese/prevenção & controle , Infecções Relacionadas à Prótese/etiologia , Infecções Relacionadas à Prótese/epidemiologia , Antibacterianos/uso terapêutico , Antibacterianos/administração & dosagem , Artroplastia de Substituição/efeitos adversos , Vancomicina/uso terapêutico , Vancomicina/administração & dosagem , Cimentos Ósseos , Clorexidina/uso terapêutico , Clorexidina/administração & dosagem , Povidona-Iodo/uso terapêutico , Povidona-Iodo/administração & dosagem , Ensaios Clínicos Controlados Aleatórios como Assunto
15.
Pediatr Allergy Immunol Pulmonol ; 37(2): 56-59, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38864768

RESUMO

Background: Povidone, a synthetic polymer commonly used in various products such as antiseptics, cosmetics, and medications, has been associated with allergic reactions, including anaphylaxis. Despite its widespread use, cases of povidone-induced anaphylaxis, especially in children, are under-recognized. This case report aims to highlight the importance of considering povidone allergy in pediatric patients presenting with anaphylaxis. Case Presentation: We describe a 3-year-old boy who experienced anaphylaxis following the application of povidone-iodine antiseptic solution to a leg wound. He presented with generalized urticaria, angioedema, dyspnea, and cough. Prompt diagnosis and management were initiated in the emergency department. He experienced the second anaphylaxis with povidone-containing eye drops prescribed during an ophthalmology visit. Conclusions: Povidone allergy should be considered in pediatric patients presenting with anaphylaxis, especially those with idiopathic reactions or multiple drug allergies. Clinicians should emphasize patient education on label reading and the provision of adrenaline autoinjectors to prevent life-threatening reactions associated with povidone exposure.


Assuntos
Anafilaxia , Anti-Infecciosos Locais , Povidona-Iodo , Humanos , Anafilaxia/induzido quimicamente , Anafilaxia/diagnóstico , Masculino , Pré-Escolar , Povidona-Iodo/efeitos adversos , Povidona-Iodo/administração & dosagem , Anti-Infecciosos Locais/efeitos adversos , Anti-Infecciosos Locais/administração & dosagem , Hipersensibilidade a Drogas/diagnóstico , Hipersensibilidade a Drogas/etiologia , Epinefrina/administração & dosagem , Epinefrina/efeitos adversos , Soluções Oftálmicas/efeitos adversos
17.
Surgery ; 176(2): 371-378, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38825398

RESUMO

BACKGROUND: The irrigation efficacy of a povidone-iodine solution to prevent surgical site infection is still controversial. We assessed the irrigation effect with a povidone-iodine solution on the incidence of surgical site infection after gastroenterological surgery. METHODS: This study is a single-center, prospective, randomized, blinded-end point superiority trial for surgical wound irrigation. Patients undergoing gastroenterological surgery were randomly assigned in a 1:1 replacement ratio using computer-generated randomization. Patients were grouped according to their surgical wound treatment into the control group using the normal sterile saline and the povidone-iodine group using 10% povidone-iodine solution after the NS solution. The main finding was 30-day surgical site infections assessed in the full analysis set. RESULTS: From November 2020 to December 2022, 697 of 894 patients were eligible for the study, among which 347 were in the povidone-iodine group and 350 in the control group. Thirty-day surgical site infections occurred in 100 (14%) patients-54 (16%) in the povidone-iodine group and 46 (13%) in the control group (odds ratio, 1.229; 95% CI, 0.800-1.889; P = .406). Superficial incisional surgical site infections occurred in 30 (9%) and 15 (4%) patients, respectively (odds ratio, 2.154; 95% CI, 1.134-4.090; P = .026). Only 3 patients (1%) in the control group developed adverse skin reactions. CONCLUSION: This study examined the irrigation efficacy of povidone-iodine for surgical site infection prevention compared to control in gastroenterological surgery. Povidone-iodine wound irrigation has shown no additional beneficial effect on the occurrence of surgical site infections.


Assuntos
Anti-Infecciosos Locais , Procedimentos Cirúrgicos do Sistema Digestório , Povidona-Iodo , Infecção da Ferida Cirúrgica , Irrigação Terapêutica , Humanos , Povidona-Iodo/administração & dosagem , Povidona-Iodo/uso terapêutico , Infecção da Ferida Cirúrgica/prevenção & controle , Infecção da Ferida Cirúrgica/epidemiologia , Infecção da Ferida Cirúrgica/etiologia , Masculino , Feminino , Irrigação Terapêutica/métodos , Pessoa de Meia-Idade , Anti-Infecciosos Locais/administração & dosagem , Estudos Prospectivos , Idoso , Procedimentos Cirúrgicos do Sistema Digestório/efeitos adversos , Adulto , Incidência , Resultado do Tratamento
18.
JAMA ; 332(7): 541-549, 2024 08 20.
Artigo em Inglês | MEDLINE | ID: mdl-38884982

RESUMO

Importance: Preoperative skin antisepsis is an established procedure to prevent surgical site infections (SSIs). The choice of antiseptic agent, povidone iodine or chlorhexidine gluconate, remains debated. Objective: To determine whether povidone iodine in alcohol is noninferior to chlorhexidine gluconate in alcohol to prevent SSIs after cardiac or abdominal surgery. Design, Setting, and Participants: Multicenter, cluster-randomized, investigator-masked, crossover, noninferiority trial; 4403 patients undergoing cardiac or abdominal surgery in 3 tertiary care hospitals in Switzerland between September 2018 and March 2020 were assessed and 3360 patients were enrolled (cardiac, n = 2187 [65%]; abdominal, n = 1173 [35%]). The last follow-up was on July 1, 2020. Interventions: Over 18 consecutive months, study sites were randomly assigned each month to either use povidone iodine or chlorhexidine gluconate, each formulated in alcohol. Disinfectants and skin application processes were standardized and followed published protocols. Main Outcomes and Measures: Primary outcome was SSI within 30 days after abdominal surgery and within 1 year after cardiac surgery, using definitions from the US Centers for Disease Control and Prevention's National Healthcare Safety Network. A noninferiority margin of 2.5% was used. Secondary outcomes included SSIs stratified by depth of infection and type of surgery. Results: A total of 1598 patients (26 cluster periods) were randomly assigned to receive povidone iodine vs 1762 patients (26 cluster periods) to chlorhexidine gluconate. Mean (SD) age of patients was 65.0 years (39.0-79.0) in the povidone iodine group and 65.0 years (41.0-78.0) in the chlorhexidine gluconate group. Patients were 32.7% and 33.9% female in the povidone iodine and chlorhexidine gluconate groups, respectively. SSIs were identified in 80 patients (5.1%) in the povidone iodine group vs 97 (5.5%) in the chlorhexidine gluconate group, a difference of 0.4% (95% CI, -1.1% to 2.0%) with the lower limit of the CI not exceeding the predefined noninferiority margin of -2.5%; results were similar when corrected for clustering. The unadjusted relative risk for povidone iodine vs chlorhexidine gluconate was 0.92 (95% CI, 0.69-1.23). Nonsignificant differences were observed following stratification by type of surgical procedure. In cardiac surgery, SSIs were present in 4.2% of patients with povidone iodine vs 3.3% with chlorhexidine gluconate (relative risk, 1.26 [95% CI, 0.82-1.94]); in abdominal surgery, SSIs were present in 6.8% with povidone iodine vs 9.9% with chlorhexidine gluconate (relative risk, 0.69 [95% CI, 0.46-1.02]). Conclusions and Relevance: Povidone iodine in alcohol as preoperative skin antisepsis was noninferior to chlorhexidine gluconate in alcohol in preventing SSIs after cardiac or abdominal surgery. Trial Registration: ClinicalTrials.gov Identifier: NCT03685604.


Assuntos
Anti-Infecciosos Locais , Antissepsia , Clorexidina , Etanol , Povidona-Iodo , Cuidados Pré-Operatórios , Infecção da Ferida Cirúrgica , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Abdome/cirurgia , Anti-Infecciosos Locais/administração & dosagem , Antissepsia/métodos , Procedimentos Cirúrgicos Cardíacos/efeitos adversos , Clorexidina/administração & dosagem , Clorexidina/análogos & derivados , Estudos Cross-Over , Etanol/administração & dosagem , Povidona-Iodo/administração & dosagem , Cuidados Pré-Operatórios/métodos , Pele/microbiologia , Infecção da Ferida Cirúrgica/epidemiologia , Infecção da Ferida Cirúrgica/prevenção & controle , Adulto , Incidência
20.
Int Forum Allergy Rhinol ; 14(9): 1525-1528, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38869489

RESUMO

KEY POINTS: PVP-I is a widely used antiseptic but only recently proposed for intranasal use. The extent of iodine absorption from available PVP-I nasal products is unknown. Iodine absorption from use of Nasodine (0.5% PVP-I nasal spray) is not clinically significant.


Assuntos
Anti-Infecciosos Locais , Iodo , Sprays Nasais , Povidona-Iodo , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Administração Intranasal , Anti-Infecciosos Locais/administração & dosagem , Anti-Infecciosos Locais/efeitos adversos , Anti-Infecciosos Locais/farmacocinética , Iodo/administração & dosagem , Iodo/efeitos adversos , Povidona-Iodo/administração & dosagem , Povidona-Iodo/farmacocinética , Povidona-Iodo/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA